|
1
|
Global Burden of Disease Liver Cancer
Collaboration. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu
MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, et al: The
burden of primary liver cancer and underlying etiologies from 1990
to 2015 at the global, regional, and national level: Results from
the global burden of disease study 2015. JAMA Oncol. 3:1683–1691.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
El-Serag HB: Hepatocellular carcinoma:
Recent trends in the United States. Gastroenterology. 127 (Suppl
1):S27–S34. 2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Munoz N and Bosch X: Epidemiology of
hepatocellular carcinoma. In: Neoplasms of the liver. Okuda K and
Ishak KG (eds). Springer, Tokyo, p3, 1989.
|
|
4
|
Davila JA, Morgan RO, Shaib Y, McGlynn KA
and El-Serag HB: Hepatitis C infection and the increasing incidence
of hepatocellular carcinoma: A population-based study.
Gastroenterology. 127:1372–1380. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sanoff HK, Chang Y, Lund JL, O'Neil BH and
Dusetzina SB: Sorafenib effectiveness in advanced hepatocellular
carcinoma. Oncologist. 21:1113–1120. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tohyama O, Matsui J, Kodama K, Hata-Sugi
N, Kimura T, Okamoto K, Minoshima Y, Iwata M and Funahashi Y:
Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor
that targets multiple receptor tyrosine kinases in preclinical
human thyroid cancer models. J Thyroid Res.
2014(638747)2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Motzer RJ, Hutson TE, Glen H, Michaelson
MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B,
et al: Lenvatinib, everolimus, and the combination in patients with
metastatic renal cell carcinoma: A randomised, phase 2, open-label,
multicentre trial. Lancet Oncol. 16:1473–1482. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellularcarcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Matsuki M, Hoshi T, Yamamoto Y,
Ikemori-Kawada M, Minoshima Y, Funahashi Y and Matsui J: Lenvatinib
inhibits angiogenesis and tumor fibroblast growth factor signaling
pathways in human hepatocellular carcinoma models. Cancer Med.
7:2641–2653. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Morishita A, Iwama H, Fujihara S, Sakamoto
T, Fujita K, Tani J, Miyoshi H, Yoneyama H, Himoto T and Masaki T:
MicroRNA profiles in various hepatocellular carcinoma cell lines.
Oncol Lett. 12:1687–1692. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liang LH and He XH: Macro-management of
microRNAs in cell cycle progression of tumor cells and its
implications in anti-cancer therapy. Acta Pharmacol Sin.
32:1311–1320. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Miyata M, Morishita A, Sakamoto T, Katsura
A, Kato K, Nishioka T, Toyota Y, Fujita K, Maeda E, Nomura T, et
al: MicroRNA profiles in cisplatin-induced apoptosis of
hepatocellular carcinoma cells. Int J Oncol. 47:535–542.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Futami T, Okada H, Kihara R, Kawase T,
Nakayama A, Suzuki T, Kameda M, Shindoh N, Terasaka T, Hirano M and
Kuromitsu S: ASP5878, a novel inhibitor of FGFR1, 2, 3, and 4,
inhibits the growth of FGF19-expressing hepatocellular carcinoma.
Mol Cancer Ther. 16:68–75. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kim SY, Kim SM, Chang HJ, Kim BW, Lee YS,
Park CS, Park KC and Chang HS: SoLAT (sorafenib lenvatinib
alternating treatment): A new treatment protocol with alternating
sorafenib and lenvatinib for refractory thyroid cancer. BMC Cancer.
18(956)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ogasawara S, Mihara Y, Kondo R, Kusano H,
Akiba J and Yano H: Antiproliferative effect of lenvatinib on human
liver cancer cell lines in vitro and in vivo. Anticancer Res.
39:5973–5982. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhao H, Lv F, Liang G, Huang X, Wu G,
Zhang W, Yu L, Shi L and Teng Y: FGF19 promotes
epithelial-mesenchymal transition in hepatocellular carcinoma cells
by modulating the GSK3β/β-catenin signaling cascade via FGFR4
activation. Oncotarget. 7:13575–13586. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Latasa MU, Salis F, Urtasun R,
Garcia-Irigoyen O, Elizalde M, Uriarte I, Santamaria M, Feo F,
Pascale RM, Prieto J, et al: Regulation of amphiregulin gene
expression by β-catenin signaling in human hepatocellular carcinoma
cells: A novel crosstalk between FGF19 and the EGFR system. PLoS
One. 7(e52711)2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY
and Cheng AL: Down-regulation of phospho-Akt is a major molecular
determinant of bortezomib-induced apoptosis in hepatocellular
carcinoma cells. Cancer Res. 68:6698–6707. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ
and Cheng AL: Synergistic interactions between sorafenib and
bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt
inactivation. J Hepatol. 52:88–95. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Matsui J, Funahashi Y, Uenaka T, Watanabe
T, Tsuruoka A and Asada M: Multi-kinase inhibitor E7080 suppresses
lymph node and lung metastases of human mammary breast tumor
MDA-MB-231 via inhibition of vascular endothelial growth
factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res.
14:5459–5465. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Matsui J, Yamamoto Y, Funahashi Y,
Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T and Asada M: E7080,
a novel inhibitor that targets multiple kinases, has potent
antitumor activities against stem cell factor producing human small
cell lung cancer H146, based on angiogenesis inhibition. Int J
Cancer. 122:664–671. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ikuta K, Yano S, Trung VT, Hanibuchi M,
Goto H, Li Q, Wang W, Yamada T, Ogino H, Kakiuchi S, et al: E7080,
a multi-tyrosine kinase inhibitor, suppresses the progression of
malignant pleural mesothelioma with different proangiogenic
cytokine production profiles. Clin Cancer Res. 15:7229–7237.
2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Jing C, Gao Z, Wang R, Yang Z, Shi B and
Hou P: Lenvatinib enhances the antitumor effects of paclitaxel in
anaplastic thyroid cancer. Am J Cancer Res. 7:903–912.
2017.PubMed/NCBI
|
|
25
|
Han Q, Zhao H, Jiang Y, Yin C and Zhang J:
HCC-derived exosomes: critical player and target for cancer immune
escape. Cells. 8(558)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yu LX, Zhang BL, Yang Y, Wang MC, Lei GL,
Gao Y, Liu H, Xiao CH, Xu JJ, Qin H, et al: Exosomal microRNAs as
potential biomarkers for cancer cell migration and prognosis in
hepatocellular carcinoma patient-derived cell models. Oncol Rep.
41:257–269. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Deng M, Zeng C, Lu X, He X, Zhang R, Qiu
Q, Zheng G, Jia X, Liu H and He Z: miR-218 suppresses gastric
cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis
in a feedback loop. Cancer Lett. 403:175–185. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sun R, Liu Z, Tong D, Yang Y, Guo B, Wang
X, Zhao L and Huang C: miR-491-5p, mediated by Foxi1, functions as
a tumor suppressor by targeting Wnt3a/β-catenin signaling in the
development of gastric cancer. Cell Death Dis.
8(e2714)2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lu L, Cai M, Peng M, Wang F and Zhai X:
miR-491-5p functions as a tumor suppressor by targeting IGF2 in
colorectal cancer. Cancer Manag Res. 11:1805–1816. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lv QL, Du H, Liu YL, Huang YT, Wang GH,
Zhang X, Chen SH and Zhou HH: Low expression of microRNA-320b
correlates with tumorigenesis and unfavorable prognosis in glioma.
Oncol Rep. 38:959–966. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Lu Y, Yang L, Qin A, Qiao Z, Huang B,
Jiang X and Wu J: miR-1470 regulates cell proliferation and
apoptosis by targeting ALX4 in hepatocellular carcinoma. Biochem
Biophys Res Commun. 522:716–723. 2020.PubMed/NCBI View Article : Google Scholar
|
